Gilead Sciences 2012 Annual Report Download - page 6

2012 was an exceptional year for Gilead
Sciences. The company achieved revenues
of $9.7 billion, including product sales of
$9.4 billion, and delivered its medicines to a
record number of people with serious diseases
around the world. Importantly, significant
progress was made advancing R&D programs
across our therapeutic areas.
June 22, 2012 marked the 25th anniversary
of Gilead’s founding. The company has grown
rapidly from a biotech start-up to a multi-
national biopharmaceutical company with over
5,000 employees spanning 26 countries on
four continents. The organization is inspired
by the opportunity to address the needs of
patients and those involved in improving
patient care: patients like Katie (cover) and
Jamie (page 3), physicians like Edward Gane
(page 5), and healthcare providers such as
Tessa St. Rose (page 7).
HIV/AIDS
Scientific advancements—in drug design,
formulation and delivery—and public health
advancements—in disease awareness, screen-
ing and linkage to care—collectively have
stemmed the global HIV/AIDS epidemic. This
is a remarkable statement to make—30 years
into the AIDS pandemic, and after 30 million
lives lost. At the International AIDS Conference
in Washington, DC in July 2012, a new optimism
emerged, fueled by improvements in HIV pre-
vention, diagnosis and care around the world.
Gilead remains at the forefront of advancing
HIV treatment through the development of
new single tablet regimens. In August 2012,
the U.S. Food and Drug Administration (FDA)
approved Stribild,
® the company’s third single
tablet regimen. Stribild combines four medi-
cations into a complete HIV treatment regimen
in a once-daily pill. This approach helps allow
patients to adhere to a fully suppressive
course of therapy more easily and consis-
tently, which is critical for the successful
management of the disease. Our commercial
organization introduced the product imme-
diately following its approval. In 2012, Stribild,
along with Atripla® and Complera,
® achieved
close to $4 billion in product sales.
The long-term goal is to ensure that all HIV
patients, working with their prescribers, have
the option to choose a single tablet regimen
that may be right for them. Important progress
was made in the development program for
tenofovir alafenamide (TAF; GS-7340), a
nucleotide reverse transcriptase inhibitor.
TAF may be able to exhibit greater antiviral
efficacy than Viread® at a dose that is 10 times
lower, which could help to improve tolerability
of therapy. Interim findings from an ongoing
Phase 2 study showed that a TAF-containing
single tablet regimen achieved a similar
virologic response to Stribild. In early 2013,
we initiated the first Phase 3 study evaluating
TAF as part of a single tablet regimen.
In July 2012, the U.S. FDA approved Truvada®
for pre-exposure prophylaxis (PrEP)—marking
the first time a product has been approved for
reducing the risk of HIV infection in high-risk
adults in combination with safer sex practices.
This key advancement in the fight against HIV
was the result of decades of work involving
investigators, academic and medical institutions,
funding agencies and more than 20,000
clinical trial participants around the world.
In addition to clinical interventions such as
PrEP, Gilead continued to support educa-
tion and outreach to increase access to HIV
testing and care worldwide. Our partners
have conducted more than 300,000 HIV tests,
which represents an important contribution to
public health by helping to diagnose infected
individuals and connect them to care. In
November 2012, the U.S. Preventive Services
Task Force recommended routine HIV testing
TO OUR
STOCKHOLDERS,
EMPLOYEES
& FRIENDS:
Left to right: Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs; Kevin Young CBE, Executive Vice President,
Commercial Operations; Robin L. Washington, Senior Vice President and Chief Financial Officer; John C. Martin, PhD, Chairman and
Chief Executive Officer; Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific
Officer; Katie L. Watson, Senior Vice President, Human Resources; John F. Milligan, PhD, President and Chief Operating Officer
8 9